Katrin Ericson, PhD, is the Executive Director of the RUNX1 Research Program (RRP), a research and advocacy non-profit venture committed to funding world-class, innovative and cross-disciplinary cancer research to find a cure for those with inherited RUNX1 mutations. She is responsible for developing global research strategies, patient outreach and engagement, and education initiatives for both the medical and patient communities. Before RRP, she was a leader within the Medical Affairs department at Amgen, Inc. for close to 8 years. There she led teams in multiple therapeutic areas, but predominantly within Hematology/Oncology. Dr. Ericson was a strategic partner for both drug development and commercialization plans, working on medicines in early-stage and late-stage clinical trials.